Skip to content

Study · Non-randomized trial · n = 13 · 2011

4 results

Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.

Makimura H, Stanley TL, Chen CY, Branch KL, Grinspoon SK

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society30 Apr 2011Cited by 5 (Europe PMC)

PMID21531600 (opens in a new tab)PMCIDPMC3112279 (opens in a new tab)DOI10.1016/j.ghir.2011.03.009 (opens in a new tab)PepBankPUB-21531600
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In men with BMI 20-35 kg/m2, 2 weeks of tesamorelin increased endogenous GH release.

    In plain wordsIn men with a BMI of 20 to 35, 2 weeks of tesamorelin increased the body's own growth hormone release.

    Peptide
    Tesamorelin
    Outcome
    IncreaseEndogenous GH release
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Two-week treatment with tesamorelin increased endogenous GH release and IGF-1
    1 context sentence
    Summary · context
    A 2-week interventional study with tesamorelin was conducted at an academic medical center in 13 men with BMI 20-35 kg/m(2).
  2. 02HumanNon-randomized trialEfficacy outcome

    In men with BMI 20-35 kg/m2, 2 weeks of tesamorelin increased IGF-1.

    In plain wordsIn men with a BMI of 20 to 35, 2 weeks of tesamorelin increased IGF-1.

    Peptide
    Tesamorelin
    Outcome
    IncreaseIGF-1
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Two-week treatment with tesamorelin increased endogenous GH release and IGF-1
    1 context sentence
    Summary · context
    A 2-week interventional study with tesamorelin was conducted at an academic medical center in 13 men with BMI 20-35 kg/m(2).
  3. 03HumanNon-randomized trialEfficacy outcome

    In men with BMI 20-35 kg/m2, 2 weeks of tesamorelin did not significantly change total adiponectin.

    In plain wordsIn men with a BMI of 20 to 35, 2 weeks of tesamorelin did not significantly change total adiponectin.

    Peptide
    Tesamorelin
    Outcome
    No significant changeTotal adiponectin
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Measurements

    Change in total adiponectin
    −0.16
    tesamorelin

    Source sentences

    Summary
    neither total (change -0.16±0.64; P=0.40)
    1 context sentence
    Summary · context
    A 2-week interventional study with tesamorelin was conducted at an academic medical center in 13 men with BMI 20-35 kg/m(2).
  4. 04HumanNon-randomized trialEfficacy outcome

    In men with BMI 20-35 kg/m2, 2 weeks of tesamorelin did not significantly change HMW adiponectin.

    In plain wordsIn men with a BMI of 20 to 35, 2 weeks of tesamorelin did not significantly change high molecular weight adiponectin.

    Peptide
    Tesamorelin
    Outcome
    No significant changeHigh molecular weight adiponectin
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Measurements

    Change in HMW adiponectin
    0.03
    tesamorelin

    Source sentences

    Summary
    nor HMW (change +0.03±0.70; P=0.87)
    1 context sentence
    Summary · context
    A 2-week interventional study with tesamorelin was conducted at an academic medical center in 13 men with BMI 20-35 kg/m(2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT00850564

Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Massachusetts General Hospitaln = 15Feb 2009 to Apr 2010

Healthy Volunteers

Trial pageClinicalTrials.govUpdated 19 Apr 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.